美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物科技指數ETF-iShares Nasdaq

202.40

+0.40000.20%

盤前：204.001.60+0.79%06:51 EDT

成交量：109.88萬

成交額：2.23億

市值：103.12億

市盈率：32.07

高：204.16

開：202.49

低：200.98

收：202.00

52周最高：217.12

52周最低：138.79

股本：5,095.00萬

流通股本：5,095.00萬

量比：0.64

換手率：2.16%

股息：0.34

股息率：0.17%

每股收益(TTM):6.31

每股收益(LYR):35.34

淨資產收益率：24.54%

總資產收益率：0.10%

市淨率：1.27

市盈率(LYR):5.73

資料載入中...

總覽公司新聞資訊公告

安進上調全年業績預期且第二季度業績超預期，股價飆升至歷史新高

券商觀點：吉利德艾滋病業務實力蓋過長期競爭擔憂

行業觀察：安進憑藉重磅藥物、生物類似藥及蓄勢待發的研發管線持續積聚勢頭

吉利德科學高管：Q2艾滋病治療市場趨軟，ACA税收補貼取消致部分民眾失去醫保覆蓋

吉利德科學高管：今年暫無計劃進行大規模併購交易

安進二季度強勁藥品銷售，上調預期，將終止早期減肥藥研發

环球市场播报

吉利德科學於2026年8月4日公布了2026年第二季度財務業績。總收入按年增長10%達到78億美元主要得益於不包括Vek

安進高管表示，預計第三季度運營支出將出現顯著的按月增長。

安進高管重申：2026年資本支出預計約26億美元，用於擴大產能，含Maritide上市準備

安進高管：Q2資本支出達5億美元，聚焦全美製造基地投資——電話會議紀要

安進高管在電話會議上表示，第二季度資本支出達5億美元，主要受美國各地生產基地投資推動。

吉利德高管在電話會議中宣佈：全年HIV業務增長預期上調至9%-10%，此前指引為8%

吉利德高管：距FDA PDUFA日期僅剩五個月，Anito-Cel細胞療法上市籌備工作已全面啓動

吉利德科學第二季度調整後每股收益-6.75美元，高於IBES預估-7.24美元

安進(AMGN)股票8月4日收盤上漲3.03%：關鍵驅動因素揭曉

TradingKey中文

吉利德科學：季度調整後每股虧損6.75美元，反映近期收購帶來的每股9.08美元知識產權研發及税務支出

安進第二季度銷售額增長9%，利潤超出華爾街預期

吉利德第二季度銷售額增長8%，超出華爾街預期

前瞻：安進股價在財報公布前走高

Vertex 擴大領導團隊，為下一階段增長注入強勁動力

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/IBB/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指數ETF-iShares Nasdaq","latestPrice":202.4,"timestamp":1789588800000,"preClose":202,"halted":0,"volume":1098798,"hourTrading":{"tag":"盘前","latestPrice":204,"preClose":202.4,"latestTime":"06:51 EDT","volume":10,"amount":2038.6436,"timestamp":1789642270611,"change":1.6,"changeRate":0.007905,"amplitude":0.037549},"delay":0,"changeRate":0.0019801980198020084,"floatShares":50950000,"shares":50950000,"eps":6.311863,"marketStatus":"盤前交易","change":0.4,"latestTime":"09-17 07:02:31 EDT","open":202.49,"high":204.1599,"low":200.98,"amount":222834762.01068002,"amplitude":0.015742,"askPrice":204.99,"askSize":300,"bidPrice":203.01,"bidSize":300,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":202.4,"sharesOutstanding":49450000,"nav":202.074365,"aum":10376518642.75,"dividendRate":0.00168,"bidAskSpread":0.000288,"preHourTrading":{"tag":"盘前","latestPrice":204,"preClose":202.4,"latestTime":"06:51 EDT","volume":10,"amount":2038.6436,"timestamp":1789642270611,"change":1.6,"changeRate":0.007905,"amplitude":0.037549},"postHourTrading":{"tag":"盘后","latestPrice":202,"preClose":202.4,"latestTime":"19:51 EDT","volume":4819,"amount":973909.5218,"timestamp":1789602686411,"change":-0.4,"changeRate":-0.001976,"amplitude":0.001976},"volumeRatio":0.6430874527691461,"impliedVol":0.2493,"impliedVolPercentile":0.748},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":50950000,"roa":"0.10%","roe":"24.54%","lyrEps":35.344796,"volumeRatio":0.6430874527691461,"shares":50950000,"dividePrice":0.34,"high":204.1599,"amplitude":0.015742,"preClose":202,"low":200.98,"week52Low":138.785,"pbRate":"1.27","psRate":"248.11","week52High":217.12,"institutionHeld":0,"latestPrice":202.4,"eps":6.311863,"divideRate":0.00168,"volume":1098798,"delay":0,"ttmEps":6.311863,"open":202.49,"prevYearClose":168.77,"prevWeekClose":202.93,"prevMonthClose":209.05,"prevQuarterClose":190.19,"fiveDayClose":205.49,"twentyDayClose":203.56,"sixtyDayClose":177},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"IBB","amount":0.011194,"announcedDate":"2026-09-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-18"},{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.0858219,"currency":"USD"},{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657523142","title":"安進上調全年業績預期且第二季度業績超預期，股價飆升至歷史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523142","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657523142?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 22:40","pubTimestamp":1785940823,"startTime":"0","endTime":"0","summary":"BUZZ-安进上调全年业绩预期且第二季度业绩超预期，股价飙升至历史新高8月5日-** 安进公司（AMGN.O）股价在早盘交易中飙升6.5%，创下415.51美元的历史新高** 该股此前52周最高价为398美元** 这家制药巨头 (link) 周二晚间公布第二季度营收为101亿美元，远超华尔街预期的94.2亿美元** 第二季度调整后每股收益为6.29美元；据伦敦证券交易所集团（LSEG）汇编的数据，","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4T4421SK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU2112291526.USD","LU1057294990.SGD","PJP","BK4588","SG9999001440.SGD","IBB","BK4533","LU0320765992.SGD","BBH","BK4534","LU1571399168.USD","LU1061106388.HKD","BK4566","LU0868494617.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","BK4581","LU2242652126.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0289739699.SGD","BK4139","LU1983299246.USD","IE0002141913.USD","LU0058720904.USD","LU2468319806.SGD","LU2089984988.USD","TBXU","AMGN","BK4585","LU0889565916.HKD","IE0009355771.USD","LU0109394709.USD","PBE","LU0122379950.USD","IE00BFTCPJ56.SGD","BK4599","IBBQ","LU2242646821.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657142645","title":"券商觀點：吉利德艾滋病業務實力蓋過長期競爭擔憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2657142645","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657142645?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:51","pubTimestamp":1785919863,"startTime":"0","endTime":"0","summary":"BUZZ-券商观点：吉利德艾滋病业务实力盖过长期竞争担忧8月5日-** 吉利德科学公司（GILD.O）周二公布（link），其第二季度产品销售额增长8%，主要得益于艾滋病治疗药物需求的强劲，但由于近期收购相关的费用，该公司报告了季度亏损** 该公司股价在盘前交易中微幅下跌艾滋病业务表现亮眼** Truist证券(“买入”评级，目标价：150美元) 表示，GILD的艾滋病业务线仍是持久的增长动力，且","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","BK4583","LU0882574055.USD","LU1571399168.USD","SG9999015952.SGD","BK4566","BK4585","TBXU","IBBQ","LU1057294990.SGD","LU1066051498.USD","BK4139","LU0058720904.USD","IE00BSNM7G36.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU0114720955.EUR","LU2324357040.USD","LU0234570918.USD","TMED","LU1934455194.USD","BIB","LU0823416689.USD","LU1037948541.HKD","LU2468319806.SGD","LU0122379950.USD","IE00BKVL7J92.USD","LU2089984988.USD","LU0109394709.USD","BK4588","IE00BZ1G4Q59.USD","IBB","BK4532","LU2112291526.USD","BK4568","IE00B7SZLL34.SGD","SG9999015945.SGD","BK4578","BBH","LU1061106388.HKD","LU1778281490.HKD","LU0965509101.SGD","SG9999015978.USD","LU1585245621.USD","BMED","LU0965509283.SGD","IE00B19Z3B42.SGD","LU1674673428.USD","LU1674673691.USD","GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657511192","title":"行業觀察：安進憑藉重磅藥物、生物類似藥及蓄勢待發的研發管線持續積聚勢頭","url":"https://stock-news.laohu8.com/highlight/detail?id=2657511192","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657511192?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:24","pubTimestamp":1785918294,"startTime":"0","endTime":"0","summary":"BUZZ-行业观察：安进凭借重磅药物、生物类似药及蓄势待发的研发管线持续积聚势头8月5日-** 生物技术公司安进（Amgen）AMGN.O报告称，第二季度营收 (link) 增长了9%，这主要得益于其胆固醇治疗药物Repatha、骨质疏松症药物Evenity以及罕见病疗法的强劲需求，与此同时，该公司仍在继续推进其实验性减肥药MariTide的研发** 盘前交易中股价小幅上涨从研发到盈利** Tru","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4S4420QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1057294990.SGD","IBBQ","BK4533","LU2242652126.USD","IE0009355771.USD","LU2468319806.SGD","LU0320765992.SGD","BK4581","BK4139","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2089984988.USD","IE0002141913.USD","LU2112291526.USD","BK4534","LU1571399168.USD","IBB","BK4599","BK4566","IE00BJJMRZ35.SGD","BBH","LU1061106388.HKD","LU1023059063.AUD","SG9999001440.SGD","BIB","PBE","AMGN","LU0868494617.USD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","TBXU","LU0109394709.USD","PJP","LU0122379950.USD","LU2242646821.SGD","LU0889565916.HKD","LU0289739699.SGD","LU1983299246.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108157113","title":"吉利德科學高管：Q2艾滋病治療市場趨軟，ACA税收補貼取消致部分民眾失去醫保覆蓋","url":"https://stock-news.laohu8.com/highlight/detail?id=1108157113","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108157113?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:32","pubTimestamp":1785879128,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管在财报电话会议中透露，第二季度艾滋病治疗市场呈现疲软态势。究其原因，部分患者因《平价医疗法案》（ACA）税收补贴取消而失去保险计划，导致市场购买力下降，对整个行业形成冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0289739699.SGD","SG9999015945.SGD","IE00B3T34201.USD","BIB","LU0109394709.USD","LU1057294990.SGD","LU1778281490.HKD","LU2324357040.USD","BK4588","LU1061106388.HKD","LU0889565916.HKD","LU1674673691.USD","LU0320765992.SGD","LU1839511570.USD","BK4139","LU0234570918.USD","BMED","LU0122379950.USD","LU2087621335.USD","LU0965509101.SGD","IE0002270589.USD","LU1066053197.SGD","BK4585","SG9999015978.USD","SG9999015986.USD","LU0861579265.USD","LU1430594728.SGD","IE00BZ1G4Q59.USD","LU0965509010.AUD","LU2468319806.SGD","LU0058720904.USD","LU0882574055.USD","LU1934455863.HKD","LU0114720955.EUR","IE00BSNM7G36.USD","MEDI","TMED","LU0965509283.SGD","LU1066051498.USD","LU1934455277.USD","BK4532","IE00B19Z3581.USD","BK4568","IBB","LU0965508806.USD","LU1585245621.USD","TBXU","LU1037948541.HKD","LU1674673428.USD","LU1037948897.HKD","IBBQ","BBH","BK4578","LU2089984988.USD","LU2112291526.USD","BK4550","GILD","BK4566","SG9999015952.SGD","IE00B19Z3B42.SGD","LU1934455194.USD","LU1571399168.USD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","LU1023059063.AUD","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100032335","title":"吉利德科學高管：今年暫無計劃進行大規模併購交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1100032335","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100032335?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:12","pubTimestamp":1785877926,"startTime":"0","endTime":"0","summary":"吉利德科学公司高管在电话会议上表示，目前不预计今年会进行额外的大规模并购交易。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","IE00B19Z3B42.SGD","LU1037948541.HKD","LU0823416689.USD","SG9999015978.USD","LU0889565916.HKD","BK4578","LU0965509283.SGD","SG9999015945.SGD","LU0122379950.USD","SG9999015986.USD","LU1585245621.USD","LU1839511570.USD","LU1778281490.HKD","LU2112291526.USD","LU0058720904.USD","BK4588","LU1066051498.USD","LU2089984988.USD","BK4550","LU0965508806.USD","IE00BKVL7J92.USD","LU0109394709.USD","LU0965509101.SGD","LU1934455277.USD","BIB","BK4585","LU1057294990.SGD","BMED","IE00BSNM7G36.USD","IE0002270589.USD","LU1674673428.USD","LU0965509010.AUD","LU1934455194.USD","TBXU","LU2324357040.USD","IE00BZ1G4Q59.USD","LU1934455863.HKD","TMED","LU0320765992.SGD","IBB","IE00B7SZLL34.SGD","LU1066053197.SGD","LU1571399168.USD","LU1023059063.AUD","BK4532","BK4139","IE00B19Z3581.USD","LU0114720955.EUR","LU2087621335.USD","LU1037948897.HKD","LU1430594728.SGD","LU1674673691.USD","LU2468319806.SGD","SG9999015952.SGD","IBBQ","IE00B3T34201.USD","LU0289739699.SGD","BBH","LU0861579265.USD","MEDI","BK4583","BK4566","GILD","LU0234570918.USD","LU0882574055.USD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657674945","title":"安進二季度強勁藥品銷售，上調預期，將終止早期減肥藥研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2657674945","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657674945?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:11","pubTimestamp":1785877860,"startTime":"0","endTime":"0","summary":"　　$安进$公司于周二美股收盘后公布财报，第二季度强劲药品销售提振公司利润，因此上调了全年预期，但同时表示将终止一款早期减肥疗法的开发。　　这家生物技术公司周二表示，将停止AMG 513的开发，这是一款目前处于1期研究阶段的潜在减肥疗法。安进称，该研究将完成以跟踪已入组受试者。　　随着AMG 513开发的终止，安进在该领域唯一的候选药物是MariTide，该药目前正在进行针对肥胖、2型糖尿病和慢性体重管理等适应症的3期研究。","market":"sg","thumbnail":"https://static.tigerbbs.com/e910a0d7e1da6d4a41f6d581ee31760f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e910a0d7e1da6d4a41f6d581ee31760f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-05/doc-inimezkz1673958.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CURE","LU0122379950.USD","RSPH","BIB","BK4533","BK4588","PJP","BK4566","IBB","AMGN","LU0320765992.SGD","THNR","TBXU","LU0058720904.USD","PINK","IYH","NBDS","PBE","BK4599","LU2468319806.SGD","IE00BJJMRZ35.SGD","TRUH","LU0289739699.SGD","BBH","IE00BJT1NW94.SGD","BK4139","LU1983299246.USD","IE00B2B36J28.USD","FXH","LU0889565916.HKD","IBBQ","LU0868494617.USD","NVOC","LU1023059063.AUD","BK4534","BK4581","IE0002141913.USD","XLVI","IE0009355771.USD","LU2242652126.USD","MEDI","LU1571399168.USD","LU1061106388.HKD","LU0109394709.USD","IE00B4R5TH58.HKD","LU2089984988.USD","SG9999001440.SGD","LU2242646821.SGD","FHLC","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657679605","title":"吉利德科學於2026年8月4日公布了2026年第二季度財務業績。總收入按年增長10%達到78億美元主要得益於不包括Vek","url":"https://stock-news.laohu8.com/highlight/detail?id=2657679605","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657679605?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:10","pubTimestamp":1785877839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4583","IE0002270589.USD","LU0965509010.AUD","LU1057294990.SGD","IE00B7SZLL34.SGD","TBXU","BK4550","LU1061106388.HKD","LU1934455277.USD","LU0122379950.USD","LU0058720904.USD","IE00BZ1G4Q59.USD","LU0109394709.USD","LU1839511570.USD","LU1430594728.SGD","LU0965509283.SGD","LU2468319806.SGD","BBH","SG9999015986.USD","BMED","SG9999015978.USD","BK4585","IBB","IE00B19Z3B42.SGD","LU1674673428.USD","LU2324357040.USD","LU0882574055.USD","LU1037948541.HKD","BK4568","LU1066051498.USD","LU1778281490.HKD","LU1571399168.USD","IE00BKVL7J92.USD","BIB","LU0965508806.USD","LU2089984988.USD","TMED","LU0889565916.HKD","LU2087621335.USD","SG9999015952.SGD","LU0234570918.USD","LU1023059063.AUD","LU0114720955.EUR","LU0823416689.USD","IE00B19Z3581.USD","LU0861579265.USD","IBBQ","IE00BSNM7G36.USD","GILD","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657376567","title":"安進高管表示，預計第三季度運營支出將出現顯著的按月增長。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657376567","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657376567?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:02","pubTimestamp":1785877379,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4534","PBE","IE00B4R5TH58.HKD","LU1983299246.USD","LU0289739699.SGD","IE0009355771.USD","LU2242652126.USD","BK4139","LU0320765992.SGD","LU2242646821.SGD","BK4585","BK4581","LU1023059063.AUD","IE00BJJMRZ35.SGD","BK4588","LU2089984988.USD","LU1061106388.HKD","BK4533","LU0058720904.USD","BK4566","AMGN","SG9999001440.SGD","LU0109394709.USD","LU1057294990.SGD","TBXU","IBBQ","BIB","LU0868494617.USD","PJP","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0889565916.HKD","BBH","IBB","LU0122379950.USD","BK4599","LU1571399168.USD","LU2112291526.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191538261","title":"安進高管重申：2026年資本支出預計約26億美元，用於擴大產能，含Maritide上市準備","url":"https://stock-news.laohu8.com/highlight/detail?id=1191538261","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191538261?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:01","pubTimestamp":1785877307,"startTime":"0","endTime":"0","summary":"安进高管最新表态，公司将继续维持2026年资本支出约26亿美元的预期。这笔资金的核心用途，正是为了扩大制造产能——其中，Maritide的上市准备工作尤为关键。\n26亿美元，一个庞大的数字，却承载着安进对未来市场的信心与布局。产能扩张，尤其是为Maritide的上市铺路，成为了这笔巨额支出的重中之重。这不仅仅是一次简单的投资，更是对战略产品线的全力押注。\n高管在发言中强调，该预期反映了公司对生产能力持续优化的坚定承诺。从长远来看，扩大制造规模不仅是为了满足现有产品的需求，更是为了确保Maritide等关键新药能够顺利推向市场。这一举措，无疑将为公司在竞争激烈的生物制药领域构筑更坚实的护城河。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU1023059063.AUD","IE00B2B36J28.USD","LU0122379950.USD","IE00B4R5TH58.HKD","LU0058720904.USD","BK4581","IE0009355771.USD","LU1571399168.USD","LU2242652126.USD","TBXU","LU2089984988.USD","LU2242646821.SGD","BK4585","LU1983299246.USD","LU2468319806.SGD","BK4533","LU0320765992.SGD","BK4599","IE00BJT1NW94.SGD","LU0868494617.USD","BK4534","LU1061106388.HKD","BK4139","LU0289739699.SGD","BK4566","BK4588","IBBQ","PJP","PBE","LU0889565916.HKD","BBH","LU1057294990.SGD","SG9999001440.SGD","IE0002141913.USD","LU2112291526.USD","BIB","AMGN","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128189819","title":"安進高管：Q2資本支出達5億美元，聚焦全美製造基地投資——電話會議紀要","url":"https://stock-news.laohu8.com/highlight/detail?id=1128189819","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128189819?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 05:01","pubTimestamp":1785877299,"startTime":"0","endTime":"0","summary":"安进（Amgen）公司高管在电话会议中透露，第二季度资本支出高达5亿美元。这笔巨额投入的核心驱动力，正是该公司在全美多个制造基地进行的战略布局。投资浪潮席卷了美国的各个生产设施，从而推动了整体资本开支的显著增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU2112291526.USD","LU1057294990.SGD","PJP","BK4588","SG9999001440.SGD","IBB","BK4533","LU0320765992.SGD","BBH","BK4534","LU1571399168.USD","LU1061106388.HKD","BK4566","LU0868494617.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","BK4581","LU2242652126.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0289739699.SGD","BK4139","LU1983299246.USD","IE0002141913.USD","LU0058720904.USD","LU2468319806.SGD","LU2089984988.USD","TBXU","AMGN","BK4585","LU0889565916.HKD","IE0009355771.USD","LU0109394709.USD","PBE","LU0122379950.USD","IE00BFTCPJ56.SGD","BK4599","IBBQ","LU2242646821.SGD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657562205","title":"安進高管在電話會議上表示，第二季度資本支出達5億美元，主要受美國各地生產基地投資推動。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657562205","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657562205?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:59","pubTimestamp":1785877188,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LU1057294990.SGD","IBBQ","BK4533","LU2242652126.USD","IE0009355771.USD","LU2468319806.SGD","LU0320765992.SGD","BK4581","BK4139","IE00B2B36J28.USD","DUSL","IE00BJT1NW94.SGD","LU2089984988.USD","IE0002141913.USD","LU2112291526.USD","BK4534","LU1571399168.USD","IBB","BK4599","BK4566","IE00BJJMRZ35.SGD","BBH","LU1061106388.HKD","FXR","LU1023059063.AUD","SG9999001440.SGD","BIB","PBE","AMGN","LU0868494617.USD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","TBXU","LU0109394709.USD","PJP","LU0122379950.USD","LU2242646821.SGD","LU0889565916.HKD","LU0289739699.SGD","LU1983299246.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135051692","title":"吉利德高管在電話會議中宣佈：全年HIV業務增長預期上調至9%-10%，此前指引為8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135051692","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135051692?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:42","pubTimestamp":1785876147,"startTime":"0","endTime":"0","summary":"吉利德（Gilead Sciences）高管在电话会议上透露，公司已将全年HIV业务增长预期上调至9%至10%的区间。这一调整较此前8%的增长指引显著提升，展现了公司对该业务领域强劲势头的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU1057294990.SGD","LU0861579265.USD","LU1066053197.SGD","IE00BKVL7J92.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU1674673428.USD","SG9999015952.SGD","GILD","LU0823416689.USD","LU1061106388.HKD","BK4578","LU1430594728.SGD","BMED","SG9999015986.USD","IE00B7SZLL34.SGD","LU0965509283.SGD","LU0889565916.HKD","LU2089984988.USD","LU0965509010.AUD","LU1585245621.USD","BK4139","LU1037948897.HKD","LU2468319806.SGD","BK4583","LU1023059063.AUD","LU1066051498.USD","LU1674673691.USD","LU2112291526.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4585","IBB","BK4568","LU0289739699.SGD","BBH","LU0965509101.SGD","LU1934455277.USD","LU0058720904.USD","BK4566","SG9999015945.SGD","TBXU","BK4550","LU0320765992.SGD","LU1037948541.HKD","LU0234570918.USD","LU0109394709.USD","BK4532","IE00B19Z3581.USD","LU1778281490.HKD","TMED","IE00BSNM7G36.USD","LU2087621335.USD","BK4588","LU1839511570.USD","LU2324357040.USD","LU0965508806.USD","LU0122379950.USD","LU0882574055.USD","LU1934455194.USD","IBBQ","IE00B3T34201.USD","LU0114720955.EUR","MEDI","LU1934455863.HKD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145483121","title":"吉利德高管：距FDA PDUFA日期僅剩五個月，Anito-Cel細胞療法上市籌備工作已全面啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1145483121","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145483121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:42","pubTimestamp":1785876146,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）高管透露，针对其重磅细胞疗法Anito-Cel的上市准备工作已全面铺开，目前距离美国食品药品监督管理局（FDA）设定的PDUFA目标日期仅剩五个月时间。这一消息源自公司近期召开的电话会议。\n在会议中，高管进一步强调，公司正紧锣密鼓地推进各项筹备事项，以确保一旦获批，该疗法能够迅速进入市场。Anito-Cel作为一种前沿的细胞治疗产品，被视为吉利德在肿瘤学领域布局的关键一环。随着最终审批日期的临近，市场对这款疗法的商业化前景给予高度关注，而吉利德方面则展现出对既定时间表与执行能力的充分信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","SG9999015945.SGD","LU1934455863.HKD","LU0965509010.AUD","LU2324357040.USD","IE00B3T34201.USD","LU2089984988.USD","BK4568","LU2112291526.USD","LU0965509283.SGD","LU1571399168.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4550","LU0882574055.USD","BK4532","BK4588","BK4583","IE00B19Z3581.USD","LU1674673691.USD","LU1061106388.HKD","MEDI","LU0109394709.USD","LU2468319806.SGD","TMED","LU1839511570.USD","LU1674673428.USD","IBBQ","BK4585","BMED","LU1066053197.SGD","IE00B19Z3B42.SGD","GILD","LU1066051498.USD","LU0122379950.USD","BBH","LU0058720904.USD","BK4566","LU1585245621.USD","IE0002270589.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1778281490.HKD","TBXU","SG9999015978.USD","LU1430594728.SGD","LU0234570918.USD","SG9999015986.USD","LU0965508806.USD","LU1057294990.SGD","LU1037948541.HKD","LU1037948897.HKD","BK4139","LU1934455194.USD","LU0114720955.EUR","BK4578","LU0965509101.SGD","SG9999015952.SGD","IBB","LU0861579265.USD","BIB","LU1023059063.AUD","LU1934455277.USD","LU0823416689.USD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163992816","title":"吉利德科學第二季度調整後每股收益-6.75美元，高於IBES預估-7.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163992816","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163992816?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:17","pubTimestamp":1785874678,"startTime":"0","endTime":"0","summary":"8月4日，吉利德科学（Gilead Sciences）公布第二季度产品销售额达76.27亿美元。第二季度调整后每股收益为-6.75美元，优于IBES预估的-7.24美元。","market":"us","thumbnail":"https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9e7ba54e8539d48dd315975babea7852"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","GILD","IE00B3T34201.USD","LU0234570918.USD","BK4566","LU0861579265.USD","BBH","LU0965509101.SGD","LU1430594728.SGD","LU2468319806.SGD","SG9999015952.SGD","SG9999015986.USD","LU1839511570.USD","LU1037948541.HKD","TMED","IE00B19Z3B42.SGD","LU0965509010.AUD","LU2324357040.USD","BK4139","IBBQ","IE00B7SZLL34.SGD","TBXU","LU0122379950.USD","IE0002270589.USD","LU0965508806.USD","LU1023059063.AUD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU0889565916.HKD","BIB","LU0882574055.USD","LU2112291526.USD","MEDI","IE00BSNM7G36.USD","LU1934455277.USD","LU1061106388.HKD","LU0058720904.USD","BK4588","BK4550","LU1934455863.HKD","IE00BKVL7J92.USD","BK4585","LU2087621335.USD","LU1057294990.SGD","IBB","SG9999015945.SGD","LU0320765992.SGD","SG9999015978.USD","LU1037948897.HKD","IE00B19Z3581.USD","BK4568","LU0289739699.SGD","LU1778281490.HKD","LU2089984988.USD","LU0109394709.USD","LU1934455194.USD","BK4532","LU1585245621.USD","LU1571399168.USD","LU1674673691.USD","BK4583","LU1066051498.USD","BK4578","BMED","LU0965509283.SGD","LU0114720955.EUR","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657627865","title":"安進(AMGN)股票8月4日收盤上漲3.03%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2657627865","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657627865?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:16","pubTimestamp":1785874591,"startTime":"0","endTime":"0","summary":"• 安进公布的第二季度业绩超出了市场对营收和每股收益的共识预期。\n• 一款代谢健康候选药物的积极中期临床数据推动了其股价上涨。\n• 全年营收达到367.5亿美元，该公司的净利润排名位列第十。","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262074405-market-movers-amgn-20260804","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2242652126.USD","AMGN","LU2468319806.SGD","SG9999001440.SGD","LU1057294990.SGD","LU2089984988.USD","BK4566","LU0889565916.HKD","PJP","IBB","BBH","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU1023059063.AUD","IBBQ","LU1061106388.HKD","LU0058720904.USD","LU2242646821.SGD","LU0868494617.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00B2B36J28.USD","PBE","IE00BJT1NW94.SGD","LU2112291526.USD","LU0109394709.USD","TBXU","BK4139","IE0009355771.USD","BK4588","BK4599","BIB","BK4533","BK4581","LU1571399168.USD","BK4534","LU0122379950.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108344321","title":"吉利德科學：季度調整後每股虧損6.75美元，反映近期收購帶來的每股9.08美元知識產權研發及税務支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1108344321","media":"美股速递","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108344321?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:04","pubTimestamp":1785873878,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）最新季度业绩揭晓。数据显示，公司调整后每股收益为-6.75美元。这一数字背后，折射出近期收购活动所产生的重大财务影响——具体而言，每股9.08美元的知识产权研发成本与税务费用被计入。这些支出，均与公司近期完成的收购交易紧密相关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","SG9999015945.SGD","LU1934455863.HKD","LU0965509010.AUD","LU2324357040.USD","IE00B3T34201.USD","LU2089984988.USD","BK4568","LU2112291526.USD","LU0965509283.SGD","LU1571399168.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4550","LU0882574055.USD","BK4532","BK4588","BK4583","IE00B19Z3581.USD","LU1674673691.USD","LU1061106388.HKD","MEDI","LU0109394709.USD","LU2468319806.SGD","TMED","LU1839511570.USD","LU1674673428.USD","IBBQ","BK4585","BMED","LU1066053197.SGD","IE00B19Z3B42.SGD","GILD","LU1066051498.USD","LU0122379950.USD","BBH","LU0058720904.USD","BK4566","LU1585245621.USD","IE0002270589.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1778281490.HKD","TBXU","SG9999015978.USD","LU1430594728.SGD","LU0234570918.USD","SG9999015986.USD","LU0965508806.USD","LU1057294990.SGD","LU1037948541.HKD","LU1037948897.HKD","BK4139","LU1934455194.USD","LU0114720955.EUR","BK4578","LU0965509101.SGD","SG9999015952.SGD","IBB","LU0861579265.USD","BIB","LU1023059063.AUD","LU1934455277.USD","LU0823416689.USD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657569101","title":"安進第二季度銷售額增長9%，利潤超出華爾街預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2657569101","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657569101?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:04","pubTimestamp":1785873843,"startTime":"0","endTime":"0","summary":"安进第二季度销售额增长9%，利润超出华尔街预期经调整的每股收益为6.29美元，超出分析师预期上调全年营收和利润预期安进公司停止开发第二款实验性减肥药AMG 513Deena Beasley路透8月4日-安进公司周二公布，受降胆固醇药物Repatha、骨质疏松药物Evenity以及罕见病药物需求推动，第二季度销售额增长9%。季度营收同比增长10%，达到101亿美元，超过了华尔街94.2亿美元的平均预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4T4411XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU0109394709.USD","LU0058720904.USD","LU2242652126.USD","SG9999001440.SGD","PJP","IBB","BK4566","LU2112291526.USD","BK4139","LU2242646821.SGD","BK4599","LU1023059063.AUD","BK4533","LU0320765992.SGD","LU1983299246.USD","PBE","LU0889565916.HKD","BIB","TBXU","LU0289739699.SGD","LU1061106388.HKD","BK4534","AMGN","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4585","LU2468319806.SGD","IBBQ","BBH","BK4588","IE0009355771.USD","LU0868494617.USD","LU1571399168.USD","IE00BJT1NW94.SGD","LU0122379950.USD","BK4581","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","04332","LU1057294990.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657820569","title":"吉利德第二季度銷售額增長8%，超出華爾街預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2657820569","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657820569?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:02","pubTimestamp":1785873759,"startTime":"0","endTime":"0","summary":"据LSEG数据显示，该公司总营收增长10%至78亿美元，超出华尔街预期的74亿美元。第二季度，吉利德公布经调整后每股亏损为6.75美元，而华尔街分析师平均预期为7.24美元。另一款较早上市的艾滋病口服药Descovy的季度销售额猛增48%，达到9.67亿美元，增幅超出预期。吉利德表示，其肝病产品组合的销售额增长10%，达到8.77亿美元，而细胞疗法产品的销售额则下降14%，至4.17亿美元，这反映出市场竞争加剧。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4T4411XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","LU2468319806.SGD","BMED","LU1778281490.HKD","LU2089984988.USD","GILD","LU0965509010.AUD","LU0965509283.SGD","LU1037948897.HKD","IBB","SG9999015986.USD","LU0965508806.USD","LU0823416689.USD","LU1585245621.USD","IE00B19Z3581.USD","LU1066053197.SGD","SG9999015945.SGD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1934455277.USD","LU1066051498.USD","LU0058720904.USD","IE00B3T34201.USD","BK4583","LU1571399168.USD","LU0320765992.SGD","LU0109394709.USD","BK4566","BK4588","LU0882574055.USD","SG9999015978.USD","LU1674673428.USD","LU0289739699.SGD","LU0965509101.SGD","IE00B19Z3B42.SGD","LU2324357040.USD","LU0889565916.HKD","BIB","BK4139","BBH","BK4585","SG9999015952.SGD","TBXU","IBBQ","BK4568","IE00BSNM7G36.USD","LU0114720955.EUR","LU1061106388.HKD","TMED","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568090","title":"前瞻：安進股價在財報公布前走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568090","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657568090?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 01:30","pubTimestamp":1785864614,"startTime":"0","endTime":"0","summary":"BUZZ-前瞻：安进股价在财报公布前走高8月4日-** 安进AMGN.O股价周二上涨2.2%，该公司将于收盘后公布季度财报，投资者正密切关注其试验性减肥药的最新进展** 据伦敦证券交易所集团（LSEG）预测，这家生物技术公司预计将公布季度营收增长3%至94.2亿美元，而调整后每股收益则可能从6.02美元降至5.62美元** 在过去8个季度中，AMGN有7个季度达到了或超过了每股收益预期，最近一次未","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL4S4411RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00BJT1NW94.SGD","LU2112291526.USD","LU1571399168.USD","BK4599","LU0320765992.SGD","BK4581","PJP","BK4588","BK4534","LU1983299246.USD","IE0009355771.USD","LU1061106388.HKD","IE00B2B36J28.USD","LU0868494617.USD","LU0109394709.USD","LU2468319806.SGD","AMGN","IE0002141913.USD","IBBQ","IE00BJJMRZ35.SGD","BK4585","SG9999001440.SGD","LU0122379950.USD","PBE","BBH","LU0058720904.USD","BK4566","IE00B4R5TH58.HKD","LU0289739699.SGD","LU0889565916.HKD","TBXU","BK4533","LU1057294990.SGD","BK4139","LU2242646821.SGD","IBB","IE00BFTCPJ56.SGD","BIB","LU1023059063.AUD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117517951","title":"Vertex 擴大領導團隊，為下一階段增長注入強勁動力","url":"https://stock-news.laohu8.com/highlight/detail?id=1117517951","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117517951?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 20:02","pubTimestamp":1785844955,"startTime":"0","endTime":"0","summary":"宾夕法尼亚州普鲁士王，2026年8月4日——全球间接税与合规领域的“决策到防御”先锋，Vertex Inc.，今日宣布其领导团队迎来三位新成员，旨在为公司下一阶段的蓬勃发展提供坚实支撑。他们的加入，将通过对人才、区域运营及技术创新的领导力扩展，进一步强化 Vertex 的全球增长战略。在 Vertex，她将负责全球人才与企业文化战略，构建起推动业务规模化发展所需的人才储备和组织能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","IE00BJT1NW94.SGD","BK4532","IE00B19Z3581.USD","TISI","LU1069344957.HKD","LU1674673428.USD","IE00BJJMRZ35.SGD","BK4099","BBH","LU0058720904.USD","IE0002270589.USD","BK4533","IE00B19Z9Z06.USD","LU2362541513.USD","SG9999001176.USD","LU1035775433.USD","PW","LU2089984988.USD","LU0079474960.USD","BK4120","LU2362540622.SGD","IE0009355771.USD","LU0109394709.USD","LU2468319806.SGD","TM","LU0061475181.USD","IE00B19Z3B42.SGD","LU2237438978.USD","LU0289739699.SGD","LU2417539215.USD","TBXU","LU1430594728.SGD","LU0234570918.USD","BK4139","BK4604","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","BK4567","LU1559883803.SGD","LU2324357040.USD","VERX","BK4588","BK4084","IE00B2B36J28.USD","LU1815336091.USD","IE0002141913.USD","BK4585","SGXZ57979304.SGD","LU1585245621.USD","IE00B4R5TH58.HKD","LU1778281490.HKD","LU0889565916.HKD","LU1093756325.SGD","LU0757428866.USD","LU2362541273.HKD","LU2462157665.USD","IE00BZ9MQY76.HKD","BK4234","BK4023","LU0320765992.SGD","BK4555","LU1093756168.USD","IE00B894F039.SGD","LU1674673691.USD","LU0432979614.USD","SG9999001176.SGD","IBBQ","SG9999013999.USD","GNMX","03160","PBE","LU0417517546.SGD","LU2456880835.USD","LU0256863811.USD","IDNA","VRTX","LU2236285917.USD","IBB","BIB","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}